The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. This is the fastest way to end the pandemic. So we want to know: do world leaders’ actions move us closer to, or further from, an equitable outcome? The Vaccine Access Test provides a framework to answer this question based on the following metrics:

➔ **Access to COVID-19 Tools Accelerator (ACT-A):** Has this country provided financial support to the ACT-A?
➔ **Multilateral Leadership:** Has this country advanced multilateral cooperation to advance equity?
➔ **Policies:** Will this country’s policies help ensure COVID-19 vaccines are accessible to all on a global scale?
➔ **Deals:** Each deal this country has made to secure promising COVID-19 vaccine candidates is scored individually based on a set of metrics for how well they advance equity.

Each metric is worth up to 3 points and Deal Scores can earn up to 6 points. The U.K. can earn up to 15 points.

### Total Score: 7.7 out of 15

The UK has been at the forefront of multilateral cooperation to date, including significant funding for ACT-A partners and hosting events that have catalysed commitments from others. However, this commitment to equitable access is not yet reflected in the UK’s domestic approach to procurement.

The UK can improve its score by:
- Building on the success of the Global Vaccine Summit and co-hosted event at UNGA to use its G7 presidency in 2021 to leverage the resources needed for the ACT-Accelerator.
- Improving the transparency of deals being reached with pharmaceutical companies, especially on pricing.
- Ensuring procurement contracts align with the WHO’s Allocation Guidance to ensure phasing and thus adequate supply for other countries.

Check out the full methodology and scores for other deals, countries, and companies at ONE.org/VaccineAccessTest